LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

Home・Stock List・Amgen Inc

Amgen Inc

Open

SectorHealthcare

345.02 -1.27

Buy Sell

Overview

Share price change

24h

Current

Min

343.87

Max

351.72

Key metrics
By Trading Economics
Income	486M 1.8B
Sales	-1.3B 8.6B
P/E Sector Avg	22.888 49.888
EPS	5.15
Dividend yield	2.87
Profit margin	21.107
Employees	31,500
EBITDA	-2.3B 2.7B

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+2.82% upside

Dividends
By Dow Jones
Dividend yield Sector Avg	2.87% 2.38%
Next Earnings	4 Aug 2026
Next Ex Dividend date	21 Aug 2026

Market Stats
By TradingEconomics
Market Cap	-5.7B 178B
Previous open	346.29
Previous close	345.02

News Sentiment

By Acuity

12%

88%

8 / 344 Healthcare

Amgen Inc Chart

Past performance is not a reliable indicator of future results.

Related News

30 Apr 2026, 20:16 UTC

Earnings

Amgen Posts Higher 1Q Profit, Revenue

6 Apr 2026, 17:09 UTC

Major Market Movers

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

3 Feb 2026, 21:49 UTC

Earnings

Amgen Logs Higher 4Q Revenue on Double-Digit Volume Boost

6 Jan 2026, 15:14 UTC

Acquisitions, Mergers, Takeovers

Amgen Buys Dark Blue Therapeutics in Deal Worth Up to $840 Million

19 Nov 2025, 21:55 UTC

Major Market Movers

Amgen Lung Cancer Drug Gets Full Approval From FDA

30 Apr 2026, 20:01 UTC

Earnings

Amgen Sees FY26 EPS $15.62-EPS $17.10 >AMGN

30 Apr 2026, 20:01 UTC

Earnings

Amgen 1Q Worldwide Prolia Sales $727M >AMGN

30 Apr 2026, 20:01 UTC

Earnings

Amgen Sees FY26 Rev $37.1B-$38.5B >AMGN

30 Apr 2026, 20:01 UTC

Earnings

Amgen Sees FY26 Adj EPS $21.70-Adj EPS $23.10 >AMGN

30 Apr 2026, 20:01 UTC

Earnings

Amgen 1Q Adj EPS $5.15 >AMGN

30 Apr 2026, 20:01 UTC

Earnings

Amgen 1Q Rev $8.62B >AMGN

30 Apr 2026, 20:01 UTC

Earnings

Amgen 1Q Net $1.82B >AMGN

30 Apr 2026, 20:01 UTC

Earnings

Amgen 1Q EPS $3.34 >AMGN

1 Apr 2026, 20:07 UTC

Acquisitions, Mergers, Takeovers

Why 2026 Is Biotech's Comeback Year -- Barrons.com

4 Feb 2026, 19:56 UTC

Market Talk

Amgen's Strong Core Growth Offsets Wait for Weightloss Drug -- Market Talk

3 Feb 2026, 21:01 UTC

Earnings

Amgen 4Q Worldwide XGEVA Sales $447M >AMGN

3 Feb 2026, 21:01 UTC

Earnings

Amgen 4Q Worldwide Enbrel Sales $532M >AMGN

3 Feb 2026, 21:01 UTC

Earnings

Amgen 4Q Adj EPS $5.29 >AMGN

3 Feb 2026, 21:01 UTC

Earnings

Amgen 4Q Net $1.33B >AMGN

3 Feb 2026, 21:01 UTC

Earnings

Amgen 4Q Worldwide Prolia Sales $1.05B >AMGN

3 Feb 2026, 21:01 UTC

Earnings

Amgen 4Q Rev $9.9B >AMGN

3 Feb 2026, 21:01 UTC

Earnings

Amgen Sees FY Adj EPS $21.60-Adj EPS $23.00 >AMGN

3 Feb 2026, 21:01 UTC

Earnings

Amgen 4Q Worldwide Neulasta Sales $132M >AMGN

3 Feb 2026, 21:01 UTC

Earnings

Amgen Sees FY Rev $37B-$38.4B >AMGN

3 Feb 2026, 21:01 UTC

Earnings

Amgen Sees FY EPS $15.45-EPS $16.94 >AMGN

3 Feb 2026, 21:01 UTC

Earnings

Amgen 4Q EPS $2.45 >AMGN

28 Jan 2026, 17:47 UTC

Earnings

Pharma Stocks Are Close to 'Breaking Out.' Earnings Could Set Them Free. -- Barrons.com

6 Jan 2026, 14:01 UTC

Acquisitions, Mergers, Takeovers

Amgen: Deal Adds Differentiated Investigational Molecule Designed to Treat Acute Myeloid Leukemia >AMGN

6 Jan 2026, 14:01 UTC

Acquisitions, Mergers, Takeovers

Amgen Acquires Dark Blue Therapeutics in Transaction Valued at Up to $840 Million >AMGN

6 Jan 2026, 14:00 UTC

Acquisitions, Mergers, Takeovers

AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE >AMGN

Peer Comparison

Price change

Amgen Inc Forecast

Price Target

By TipRanks

2.82% upside

12 Months Forecast

Average 359.44 USD 2.82%

High 427 USD

Low 300 USD

Based on 24 Wall Street analysts offering 12 month price targets forAmgen Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

24 ratings

Buy

Hold

Sell

Based on 24 analysts giving stock ratings to Amgen Inc - Dist in the past 3 months.

Sentiment

By Acuity

8 / 344 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.